JLJulia Levina

Julia Levina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Levina has a total of 252 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Guidelines for the Management of Patients with Food Allergy

    by Leyla S. Namazova-Baranova, Aleksander A. Baranov, Anna A. Alekseeva, Eduard T. Ambarchyan, Natalya G. Astafyeva, Irina V. Vahlova, Anita R. Denisova, Olga G. Elisyutina, Marika I. Ivardava, Natalya I. Ilyina, et al.

    This article summarizes current epidemiological, etiological, and clinical aspects of food allergy in children. Evidence-based approaches to diagnosis (including differential diagnosis), treatment, and prevention are presented. Practical management algorithms for patients are outlined, developed on the basis of current scientific literature and recent clinical data on food allergy.

  • Open Access

    Current Clinical Guidelines for the Management of Patients with Eosinophilic Esophagitis

    by Oksana M. Drapkina, Vladimir T. Ivashkin, Igor V. Maev, Leyla S. Namazova-Baranova, Aleksandr A. Baranov, Musa R. Khaitov, Lyudmila M. Mikhaleva, Valeria O. Kaybysheva, Elena A. Vishneva, Evgeniy D. Fedorov, et al.

    This article presents an analysis of current clinical guidelines for the management of patients with eosinophilic esophagitis (EoE) — a chronic immune-mediated disease of the esophagus characterized by eosinophilic infiltration of the mucosa (≥ 15 eos/hpf) and clinical manifestations of esophageal dysfunction. The review highlights key changes in diagnostic approaches and discusses contemporary treatment strategies, including dietary therapy (starting with the least restrictive diets), pharmacological treatment (proton pump inhibitors, topical steroids, biologic therapy), and endoscopic dilation for strictures. The authors emphasize the need for comprehensive monitoring (clinical, endoscopic, and histological) to assess treatment response and for long-term maintenance therapy given the chronic nature of the disease. Special attention is paid to pediatric aspects of patient management.


  • Evaluation of Dupilumab Therapy of Children with Multimorbid Atopic Phenotype: Preliminary Data from an Observational Study

    by Kamilla E. Efendieva, Julia G. Levina, Vera G. Kalugina, Elena A. Vishneva, Anna A. Alekseeva, Pavel A. Levin, Leyla S. Namazova-Baranova

    Background. The genetically engineered biological drug dupilumab, which blocks the IL-4 and IL-13 signaling pathways, has demonstrated high efficacy in the treatment of Atopic Eczema (AE) in children and adults. However, there are no studies in Russia that evaluate the clinical response and the dynamics of biomarkers in children of different ages with a multimorbid atopic phenotype who receive therapy with this drug. The aim of the study is to evaluate the efficacy and safety of dupilumab, as well as to analyze the dynamics of inflammation biomarkers in children with a multimorbid atopic phenotype, including patients with moderate to severe AE. Methods. A prospective observational study included 15 children aged 6 months to 17 years 11 months. All patients received dupilumab for at least 16 weeks. Clinical efficacy was assessed using the SCORAD and EASI scales (with SCORAD-50/75/90 and EASI-50/75/90), quality of life (CDLQI), and control of concomitant diseases (ACT, VAS). Biomarkers (periostin, VEGF, DPP4, eosinophils, and FeNO) were determined before and 16 weeks after the start of therapy. Results. By the 16th week, all patients had reached SCORAD-50 and EASI-50, 80% had reached SCORAD-75, 100% had reached EASI-75, 60% had reached SCORAD-90, and 87% had reached EASI-90. During the treatment, there was a decrease in the levels of periostin (median change of –8%), VEGF (–9.7%), and a tendency towards a decrease in the number of eosinophils and FeNO, while the levels of DPP4 remained stable. The quality of life improved in most patients, and the accompanying manifestations (bronchial asthma, allergic rhinitis) were under full control. Side effects were limited to local reactions and conjunctivitis. Conclusion. Dupilumab therapy in children with a multimorbid atopic phenotype, including patients with moderate to severe AE, provides rapid and persistent clinical improvement, a decrease in the severity of inflammatory markers, and an improvement in quality of life. The data obtained confirm the efficacy and safety of the drug and indicate the prospects for using biomarkers to predict the individual response to therapy.

  • Open Access

    The Prevalence of Sensitization to Food Allergens from the Group of “Big Eight” in Children with Atopic Phenotype: Cross-Sectional Study

    by Kamilla E. Efendieva, Julia G. Levina, Vera G. Kalugina, Elena A. Vishneva, Anna A. Alekseeva, Konstantin S. Volkov, Pavel A. Levin, Leyla S. Namazova-Baranova

    Background. Food allergy (FA) is a common chronic disease. There are no official data on the prevalence of FA in Russia. The results of only a few Russian studies of FA and anaphylaxis in children have been published.The aim of the study is to study the prevalence of sensitization to food allergens from the group of “big eight” in children with atopic phenotype living in the Moscow agglomeration.Methods. The cross-sectional study included children aged 0 to 17 years with complaints of seasonal manifestations of allergies / diagnosed with seasonal allergic rhinitis (pollinosis); with complaints of allergic reactions when eating any food; with complaints of atopic dermatitis. The determination of sensitization to allergens was carried out using ImmunoCAP technology, ImmunoCAP ISAC / ALEX2 allergy chips.Results. 240 children were included in the study. Sensitization to extracts of food allergens of the “big eight”, detected by the ImmunoCAP monoplex method, was determined in 1.5 (for fish) — 5 (for wheat) several times more often than with multiplex allergodiagnostics. In molecular allergodiagnosis, sensitization to hazelnut allergens was found in 57%, peanuts — in 47%, soy — in 39%, walnut — in 24%, chicken egg — in 18%, cow’s milk — in 12%, fish — in 9.7%, cashews — in 7.6%, shrimp — in 6.3%, wheat — in 4.6% of children. The frequency of food allergy symptoms, based on the assessment of the patients’ parents, was up to 7 times higher than the detected frequency of sensitization, accompanied by complaints of symptoms when eating the appropriate foods. Among the products causing symptoms in such patients, hazelnuts, cow’s milk, chicken egg and peanuts were in the lead.Conclusion. More than half of Russian children are sensitized to the allergens of the “big eight”, while clinically significant sensitization was noted 2 times less often. Sensitization to the allergen components of the PR-10 group of hazelnuts, peanuts and soybeans was most often detected. The frequency of FA diagnosed by a doctor is significantly lower than the frequency of the disease detected by the results of a survey of patients’ parents.


  • Open Access

    New Opportunities of Dupilumab in Achieving Disease Control in Preschool Age Patients with Atopic Dermatitis: Clinical Case

    by Julia G. Levina, Polina A. Pyzhyanova, Vera G. Kalugina, Kamilla E. Efendieva, Elena A. Vishneva, Anna A. Alekseeva, Leyla S. Namazova-Baranova

    Background. Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases in children. It manifests during the first year of life in majority of cases. Early AD manifestation is a risk factor for the development of other atopic spectrum diseases in the future. Nowadays, the ability of the dupilumab, as a genetically engineered biologic drug (GEBD), to modify the disease course, to reduce the frequency of AD persistence and the possibility of multimorbid atopic phenotype development is widely discussed. Thus, dupilumab management in young children with early onset and severe course arouses specific interest. Clinical case description. This article demonstrates the experience of effective administration of GEBD dupilumab in 4-year old patient with severe AD and comorbid food allergies. Continuous therapy for 12 weeks allowed to recover disease’s skin manifestations. No adverse events were reported. Conclusion. Long-term continuous dupilumab administration in children aged from 6 months to 5 years has proven its efficacy and acceptable safety profile. The potential disease-modifying effect of dupilumab is especially significant for young and preschool children due to the high risk atopic multimorbidity developing during this period.


  • Open Access

    Food Allergy and Food Intolerance – New Developments

    by Leyla Namazova-Baranova, Kamilla Efendieva, Julia Levina, Vera Kalugina


  • Open Access

    Controversial Issues of Immunopathogenesis of Psoriasis and Atopic Dermatitis

    by Eduard T. Ambarchian, Leila S. Namazova-Baranova, Anastasiia D. Kuzminova, Vladislav V. Ivanchikov, Elena A. Vishneva, Marika I. Ivardava, Kamilla E. Efendiyeva, Juliya G. Levina

    Psoriasis (PsO) and atopic dermatitis (AD have much in common: both diseases are widespread, characterized by a chronic relapsing course, primarily affect the skin and lead to a quality reduction of life of patients, regardless of their age. The pathogenesis of these two dermatoses, which are the most common in the practice of a pediatric dermatologist, is quite different. PsO is a chronic inflammatory skin disease, the pathogenesis of which is associated with the involvement of the Th1 pathway: Th17 cells and the IL-23/IL-17 axis. AD, in turn, is usually associated with high levels of IL-4, IL-5, IL-13, IL-31 and IFN-γ produced by activated T-helper 2 (Th2) cells. The clinical symptoms and immunopathological responses of these two skin conditions tend to differ. However, patients with PsO may sometimes present with a skin rash resembling AD combined with intense itching and laboratory increase in immunoglobulin E (IgE) which may indicate the need to change the paradigm of dominance of only one type of T-inflammation in patients with these diseases.


  • Open Access

    Children with disabilities during the COVID-19 pandemic: medical and social comparative study

    by Leyla S. Namazova-Baranova, Elena A. Vishneva, Elena V. Kaytukova, Natalia V. Ustinova, Anna A. Alekseeva, George A. Karkashadze, Irina A. Belyaeva, Julia G. Levina, Nato D. Vashakmadze, Marina V. Fedoseenko, et al.

    Background. The COVID-19 pandemic is a global challenge to States and health systems. The pandemic and its consequences can have a devastating impact on the health and development of children, especially those in vulnerable situations — children with disabilities.The aim of the study is a medical and social assessment of the effect of the COVID—19 pandemic and its consequences on families with children with disabilities.Methods. A descriptive study using the Google forms platform was conducted using the cross-sectional method. Two groups of parents of children aged 0–17 years with disabilities (group 1) and without disabilities (group 2) who apply to a medical organization for preventive examinations were interviewed.Results and discussion. A total of 175 electronic questionnaires were received. Parents from 46 regions of Russia participated in the survey. A significant majority of respondents were women — 172 people (98%), 3 men (2%). More than half of the respondents are residents of the megalopolis. The study showed that the COVID-19 pandemic had a negative impact on the health and education of children and on the lifestyle and families welfare in general. It was revealed that the financial situation of many families who took part in the study worsened, which affected the living conditions of children. During the COVID-19 pandemic, the health care system was being rebuilt taking into account new tasks to counteract dangerous infection, which was reflected in changes in the provision of medical care to children, and in some cases this led to a deterioration of their health. A significant number of parents who participated in the study believe that changes in the organization of medical care during the pandemic had a negative impact on their child’s health. Among the main health problems, parents highlight delays and cancellations of medical consultations, difficulties in obtaining urgent care and problems with drug provision. Among the main health problems, parents highlight delays and cancellations of medical consultations, difficulties in obtaining emergency care and problems with drug provision. The study shows that families with disabled children have been affected by the COVID-19 pandemic to a greater extent than families raising children without chronic health problems. If the deterioration of the financial situation is almost equally revealed in both groups, then problems related to medical care and education have a more noticeable impact on families with a child with a disability. The obtained results should be taken into account in times of new challenges when developing measures of state support for families with children, especially with children with disabilities. At the same time, it is important to pay primary attention to the organization of medical care for children (continuity of planned medical care for the child population and rehabilitation actions) and educational services (providing online learning opportunities for the child, taking into account individual ones).Conclusion. The COVID-19 pandemic and its consequences have had a negative impact on the standard and quality of life of people, especially families with children. The pandemic has had a significant adverse impact on the health and development of children, especially children with disabilities. The study showed a decrease in the financial situation of families, problems with children receiving medical care, difficulties in education, especially with regard to specialized pedagogical classes with disabled children, during the pandemic. According to the study, in order to prevent the negative impact of the pandemic, it is proposed not only to provide financial support to families, but also to maintain access to the educational process with the provision of the required devices, as well as the possibility of receiving medical care for children, especially children with disabilities, including planned.

  • Open Access

    Role of Calcineurin Inhibitors in the Management of Atopic Dermatitis in Children

    by Kamilla E. Efendieva, Leyla S. Namazova-Baranova, Juliya G. Levina, Vera G. Kalugina, Anna A. Alekseeva, Elena A. Vishneva, Konstantin S. Volkov

    Atopic dermatitis (AD) is a widespread chronic inflammatory skin disease that has a significant impact on various aspects of patient's life. This review presents modern view on AD pathophysiology, its correlation with other concomitant diseases, and covers practical aspects of external anti-inflammatory therapy implementation. The analysis of clinical studies has shown the significant role of calcineurin inhibitors in the effective treatment of AD in children from its first manifestations at early age.

  • Open Access

    Multidisciplinary Approach To The Problem Of Managing Children With Frequent Respiratory Infections Of The Upper Respiratory Tract: Key Results

    by Leyla S. Namazova-Baranova, Svetlana G. Gubanova, Irina V. Zelenkova, Viktor A. Gankovskii, Marina V. Egorova, Julia G. Levina, Elena V. Kaytukova, Kamilla E. Efendieva, Elena A. Vishneva

    Background. Recurrent upper respiratory diseases in children are an urgent and common issue in pediatrics. Comorbidities often lead to prolonged, complicated, or chronic course of the inflammatory process in the upper airways.Objective. The aim of the study — scientific evidence and complex technology development for the management of children with recurrent upper respiratory diseases according to implemented multidisciplinary personalized approach, complex of modern methods for diagnosing and health monitoring to achieve long-term remission.Materials and methods. The study included 115 children aged from 2 years 6 months to 17 years 11 months with recurrent upper respiratory diseases. Examination included: nasal cavity, nasopharynx and larynx endoscopy, abdomen ultrasound with aqueous-siphon test, tympanometry, and laboratory tests (total and specific IgE levels, antistreptolysin-O, microbiological study of nasopharynx and oropharynx discharge, enzyme-linked immunosorbent assay of feces on Helicobacter pylori.Results. The study has revealed high prevalence of associated allergic pathology in children with recurrent upper respiratory diseases. Allergic rhinitis was the most common (55 (48%) children). There was also a high prevalence of gastroesophageal reflux disease (GERD) (37 (32%) children). Clinical signs of GERD were revealed in patients with chronic diseases significantly more often than in children with acute ENT pathology (27 (38%) and 10 (23%) children, respectively). It confirms the role of this comorbid condition in the development and course of chronic inflammatory process of the upper airways. Obtained data analysis has shown high prevalence of allergic and gastrointestinal pathology in children with recurrent upper respiratory diseases. Diagnostic and management algorithm for patients with recurrent upper respiratory diseases as well as practical guidelines were prepared based on the study data. This algorithm will allow to implement the personalized multidisciplinary approach for the management of prior and comorbid diseases via modern informative diagnostic methods. The complex approach to timely physical examination and pathogenetic treatment will ensure control of the patient’s condition and prevent the development of chronic ENT organ pathology in children.